Nanite Inc. has been awarded a $1.8 million grant by the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.
Novel HIV-1 vaccine strategies should elicit potent and broad immunity against the viral envelope (Env) glycoprotein. Particle presentation of Env has shown promise in animal studies, but has several problems that limit their clinical application.
Gilead Sciences Inc. has patented 4'-Thionucleoside analogues acting as viral replication inhibitors reported to be useful for the treatment of HIV infection.
Scientists at Jisikai (Suzhou) Pharmaceutical Co. Ltd. and Yaopharma Co. Ltd. have disclosed polycyclic N-heterocyclic ketone compounds reported to be useful for the treatment of HIV infection.
The autophagy process, a critical regulator of T-cell function, has been shown to control acute HIV-1 infection and play a crucial role also in HIV-1 disease pathogenesis.
Researchers from Viiv Healthcare Ltd. presented preclinical data for the next-generation maturation inhibitor (MI) VH-3739937 (VH-937, zegruvirimat), currently in clinical testing for the treatment of HIV.
For the treatment of HIV infection, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used to prevent viral replication by binding to a pocket near the polymerase active site of HIV-1 reverse transcriptase.
The use of latency reversing agents is useful for reducing the HIV reservoir, but their effect on infected cells isolated from untreated people with HIV is still unknown.
Retinoids are derivatives of vitamin A that target the retinoid receptors and induce antiproliferative effects and cell death. George Washington University has tested a series of different retinoids, including alitretinoin, tazarotene and AM-80, also known as tamibarotene, for their efficacy against HIV-infected CD4+ T cells regarding their ability to enhance the cytotoxic effect of NK cells.
One topic at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held in Denver this month was that resistance to antiretroviral therapy (ART) has become a public health problem for people living with HIV. Without a vaccine or a cure, these patients depend on treatments that suppress viremia by preventing the virus from replicating. They are lifelong treatments and, until new advances succeed in eradicating the virus from reservoirs, the only option available.
RSS
